5 Amendments of Tiziana BEGHIN related to 2016/2057(INI)
Amendment 26 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Regards universal access to medicines as essential, all the more so because the economic crisis in Europe has made such access even more of a problem, in particular for the most vulnerable groups in society; urges, therefore, that these groups should be guaranteed access to medicines;
Amendment 50 #
Draft opinion
Paragraph 3 a (new)
Paragraph 3 a (new)
3a. Urges that access to medicines should be guaranteed for people in all countries, not just in those with effective innovation policies; points out that innovation does not always serve to ensure that medicines are more readily available, and indeed may have the opposite effect;
Amendment 63 #
Draft opinion
Paragraph 5
Paragraph 5
5. Urges that universal access to medicines should not be contingent on price, which should reflect a fair balance between the cost of research, industry growth and the need for sustainable welfare systems; urges that a balance should be maintained at all times between research, development and sustainability, with a view to combating the pharmaceutical oligopolies which determine the price of medicines, even when the prices in question are unsustainable for many health systems, and in so doing create vast areas in which people are denied access to medicines;
Amendment 82 #
Draft opinion
Paragraph 7
Paragraph 7
7. Reiterates that part of the reason why businesses are becoming less competitive and why welfare spending is so high is that EU rules – including rules on drug pricing – are too burdensome.; points out that price of most medicines is out of proportion to the cost of manufacturing them; emphasises, in that connection, that firms' competitive position should have no bearing on the final price of medicines;
Amendment 83 #
Draft opinion
Paragraph 7 a (new)
Paragraph 7 a (new)
7a. Points out that it is the pharmaceutical industry which is pressing for the enforcement of the rules on patents and thus preventing the use of generic drugs, which are cheaper and could thus be made more widely available; calls for information and awareness-raising campaigns to encourage the use of generic drugs;